Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | PNLIP | P16233 | 2/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.59 |
| ▸ | FADS1 | O60427 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10763914 | 0.89 | KMT2A (0.69) | KMT2APKMMEN1LMNAKDM4E | |
| SCHEMBL10615518 | 0.88 | LMNA (0.63) | KMT2APKMMEN1LMNAKDM4E | |
| SCHEMBL29375984 | 0.88 | LMNA (0.63) | KMT2APKMMEN1LMNAKDM4E | |
| SCHEMBL30031499 | 0.86 | PKM (0.73) | KMT2APKMKDM4EALOX15NPC1 | |
| SCHEMBL23796613 | 0.86 | PKM (0.73) | KMT2APKMKDM4EALOX15NPC1 | |
| SCHEMBL2130995 | 0.85 | ALDH1A1 (0.67) | KMT2APKMMEN1LMNAALOX15 | |
| Benzoylpas SCHEMBL563122 | 0.85 | KMT2A (1.00) | KMT2APKMMEN1KDM4EALOX15 | |
| SCHEMBL30031230 | 0.85 | PKM (0.71) | KMT2APKMKDM4EHSD17B10POLB | |
| SCHEMBL23796823 | 0.85 | PKM (0.71) | KMT2APKMKDM4EHSD17B10POLB | |
| SCHEMBL11788972 | 0.84 | LMNA (0.64) | KMT2APKMMEN1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207219-B2 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2012-06-26 | — | — | US | disclosed |
| US-20120095073-A1 | ION CHANNEL MODULATING ACTIVITY II | CARDIOME PHARMA CORP. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-20100120890-A1 | ION CHANNEL MODULATING ACTIVITY I | CARDIOME PHARMA CORP. (CA) | 2010-05-13 | — | — | US | disclosed |
| US-7674820-B2 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2010-03-09 | — | — | US | disclosed |
| US-20090270478-A1 | ION CHANNEL MODULATING ACTIVITY II | CARDIOME PHARMA CORP. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-7507545-B2 | Ion channel modulating activity method | CARDIOME PHARMA CORP. (CA) | 2009-03-24 | — | — | US | disclosed |
| EP-0817643-B1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20060199848-A9 | Cardiovascular disorders; antiarrhythmai agenst; sodium channel moderators; potassium channel moderators; prevent fibrillation | CARDIOME PHARMA CORP. (CA) | 2006-09-07 | — | — | US | disclosed |
| US-20060135536-A9 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2006-06-22 | — | — | US | disclosed |
| US-20050119315-A1 | Ion channel modulating activity II | CARDIOME PHARMA CORP. (CA) | 2005-06-02 | — | — | US | disclosed |
| WO-2005018635-A2 | ION CHANNEL MODULATING ACTIVITY I | CARDIOME PHARMA CORP. (CA) | 2005-03-03 | — | — | WO | disclosed |
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | JOHN HOPKINS UNIVERSITY | 2003-10-02 | — | — | US | disclosed |
| US-6569862-B1 | Adminstering xanthine oxidase inhibitor such as allopurinol | JOHNS HOPKINS UNIVERSITY | 2003-05-27 | — | — | US | disclosed |
| EP-1044002-A4 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | UNIV JOHNS HOPKINS (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6191136-B1 | ADMINISTERING XANTHINE OXIDASE INHIBITOR | JOHNS HOPKINS UNIVERSITY | 2001-02-20 | — | — | US | disclosed |
| EP-1044002-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999024038-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5674887-A | Prevention of bone resorption | ELI LILLY AND COMPANY (US) | 1997-10-07 | — | — | US | disclosed |
| US-5436258-A | Prevention of bone resorption | ELI LILLY AND COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0587378-A1 | Prevention of bone resorption | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119315-A1 | Ion channel modulating activity II | KCNH1, KCNN3, KCNJ2 | KMT2A 2416/4885PKM 2748/4885MEN1 4474/4885 |
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | TNNI3, TNNT2, RYR2 | KMT2A 3990/4885PKM 1301/4885MEN1 4636/4885 |
| US-20100120890-A1 | ION CHANNEL MODULATING ACTIVITY I | KCNN1, KCNN3, KCNH1 | KMT2A 3289/4885PKM 2004/4885MEN1 4008/4885 |
| US-20060199848-A9 | Cardiovascular disorders; antiarrhythmai agenst; sodium channel moderators; potassium channel moderators; prevent fibrillation | KCNN3, KCNN1, KCNN2 | KMT2A 921/4885PKM 1119/4885MEN1 4211/4885 |
| US-20060135536-A9 | Ion channel modulating activity I | KCNN1, KCNN3, KCNH1 | KMT2A 3289/4885PKM 2004/4885MEN1 4008/4885 |
| US-20090270478-A1 | ION CHANNEL MODULATING ACTIVITY II | KCNH1, KCNN3, KCNN2 | KMT2A 2408/4885PKM 2564/4885MEN1 4198/4885 |
| US-20120095073-A1 | ION CHANNEL MODULATING ACTIVITY II | KCNH1, KCNN3, KCNJ2 | KMT2A 2416/4885PKM 2748/4885MEN1 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.